1 |
HARBECK N, GNANT M. Breast Cancer[J]. Lancet, 2017, 389(10074):1134-1150.
|
2 |
GUO F, ZHOU X X, GUI W,et al. Clinical significance of CCN5 and mutant p53 in primary and recurrent lesions of breast cancer[J]. Am J Transl Res, 2021,13(7):8433-8437.
|
3 |
欧阳倩雯,涂剑宏,吴晓波,等. Wnt-1诱导分泌蛋白-1表达与乳腺癌预后的关系[J]. 中华乳腺病杂志(电子版),2017,11(5):277-281.
|
4 |
李月霞,任艳霞,杨晓艳,等. WISP2和Slug表达与早期低危子宫内膜腺癌远处转移及预后的关系[J]. 实用癌症杂志,2023,38(9):1466-1469.
|
5 |
SUN S Q, CUI Z, YAN T T, et al. CCN5 inhibits proliferation and promotes apoptosis of oral squamous cell carcinoma cells[J]. Cell Biol Int, 2020,44(4):998-1008.
|
6 |
AMLAN D, INAMUL H Q, PRIYANKA R, et al. CCN5 activation by free or encapsulated EGCG is required to render triple-negative breast cancer cell viability and tumor progression.[J]. Pharmacol Res Perspe, 2021,9(2):e00753.
|
7 |
FERRAND N, FERT A, MORICHON R,et al. WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells[J]. Cancers, 2022,14(6):.
|
8 |
HAQUE I, GHOSH A, ACUP S,et al. Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway[J]. BMC cancer,2018,18(1):99.
|
9 |
丰锦春,杜露,杨亮, 等. 乳腺癌患者miR-196a2基因rs11614913位点的多态性及其与癌基因表达变化的相关性[J]. 临床和实验医学杂志,2020,19(21):2272-2274.
|
10 |
GONG W, XU J, WANG G, et al. ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis[J]. Chin J Cancer Res, 2021, 33(6):637-648.
|
11 |
CHEN T T, LIU L, ZOU Y H,et al. Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma[J]. Cancer Biol Med, 2021,18(1):227-244.
|
12 |
WU T, GU X S, CUI H M. Emerging Roles of SKP2 in Cancer Drug Resistance[J]. Cells,2021,10(5):147.
|
13 |
吴金训. Skp2、P27和CyclinE在宫颈癌组织中的表达及与临床病理特征的关系[J]. 中国医药科学,2019,9(7):222-225.
|
14 |
ZOLFAGHARI S, KAASBØLL O J, MONSEN V T, et al. The carboxyl-terminal TSP1-homology domain is the biologically active effector peptide of matricellular protein CCN5 that counteracts profibrotic CCN2.[J]. J Biol Chem,2023,299(1):102803.
|
15 |
ZHOU D D, BAI W Q, ZHAI X T, et al. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR positive triple negative breast cancer[J]. Mil Med Res, 2022,9(4):419-431.
|
16 |
YU X F, MAO R Y, FENG W, et al. WISP3 suppresses ESCC progression by inhibiting the IGF-2-IGF1R-AKT signaling cascade[J]. Exp Cell Res, 2021,409(1):112871.
|
17 |
SAIM A, USMA N, AHMA D, et al. Transcriptome Analysis Reveals Vimentin-Induced Disruption of Cell-Cell Associations Augments Breast Cancer Cell Migration[J]. Cells,2022,11(24):4035.
|
18 |
ALEXANDE R, LOFTU S, ALFRED O, et al. Extracellular Vesicles From Osteotropic Breast Cancer Cells Affect Bone Resident Cells.[J]. J Bone Miner Res, 2020,35(2):396-412.
|
19 |
GIUSTI V, SCOTLANDI K. CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology[J]. J Cell Commun Signal, 2021,15(4):545-566.
|
20 |
REBOLLEDO D L, ACUÑA M J, BRANDAN E. Role of Matricellular CCN Proteins in Skeletal Muscle: Focus on CCN2/CTGF and Its Regulation by Vasoactive Peptides[J]. Int J Mol Sci, 2021, 22(10):5234.
|
21 |
BINWAQAR S H, SALAHI N, ZHONGHUA L, et al. Advanced Squamous Cell Carcinoma of Gall Bladder Masquerading as Liver Abscess With Review of Literature Review on Advanced Biliary Tract Cancer[J]. Cureus, 2021,13(8):e16867.
|
22 |
WEI F, BA S, JIN M, et al. RNF180 Inhibits Proliferation and Promotes Apoptosis of Colorectal Cancer Through Ubiquitination of WISP1[J]. Front Cell Dev Biol, 2021,8:623455.
|
23 |
JIA Q, ZHANG Y, XU B, et al. Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment[J]. Aging (Albany NY), 2021,13(17):21216-21231.
|
24 |
肖晶晶,黄美玲,延常姣,等. Her-2阳性乳腺癌新辅助化疗联合靶向治疗获得病理完全缓解的影响因素[J]. 实用医学杂志, 2022, 38(5): 542-546.
|
25 |
谭忆雯,王成龙,曹友德. 2018年ASCO/CAP乳腺癌HER2 FISH检测更新指南临床实践分析 [J]. 实用医学杂志, 2021, 37(5): 698-700.
|